Urology
A wide range of therapeutic areasWith a top selling product in its portfolio, the business unit of Urologu has gained pace and strength in the years 2012-2016. LEUPROL, a unique version of Leuprolide (inj) is a market leader and Pharmazac works with a team of experts in the field for the medical information and marketing activities.
Pharmazac is planning a number of announced and currently confidential in-house and partnership projects to expand its portfolio, exports and presence in the field of Urology with a long-term vision to become a segment leader.
Recent & Forthcoming Developments
-
Pharmazac recently launched Q-Pain, a Diclofenac improved cutaneous solution that offers immediate relief from muscular pain. The product is expected to achieve the no 2 position in the market.
-
REINOST, a revised version of Diecerein will be launched in Q1/2017, ccording to the Development Department. The product is also under registration in four (4) countries.
-
Pharmazac will announce the in-house development of a new combination of Myoskeletal molecules soon, the Product Development team feels confident that a fixed dosage combination for pain treatment will provide better solutions to patients with chronic pain and osteoarthritis.
5
Products Released
4
Products Under Development
Products
-
LEUPROL (Leuprolide/ Leuproreline Inj.)
-
BICAPROL (Bicalutamide)
Product List
-
ZOPROST (Alfuzosine tabs)
-
OMIDEX (Bicalutamide)
Forthcoming
-
Dutasteride/ Tamsulosin*
-
Tadalafil*
Under In-House Development
-
Mirabegron*
-
Tadalafil/ Dapoxetine*
* subject to patent expirations